Education-only orientation — This page is part of the iMicrodosing.org evidence library. It provides research and regulatory education only. It is not clinical advice, prescribing information, a recommendation to seek or avoid any treatment, or guidance on participating in any clinical program.
What this page does and does not contain — This page examines the clinical and regulatory landscape for psilocybin-based investigational drugs. It names clinical sponsors and trial programs only to identify their public research records and regulatory milestones. It does not: recommend or endorse any treatment, drug, or program; guide readers toward or away from any investigational therapy; facilitate trial enrollment; provide recruitment or site-location information; reproduce or endorse sponsor investor language as established efficacy; apply full-dose clinical trial findings to microdosing; or link to
.comcommerce properties.
This is not legal advice. All statements here are general educational descriptions of regulatory frameworks. Consult a qualified attorney licensed in your jurisdiction for advice applicable to your situation.
Four distinct regulatory categories are often conflated in psilocybin coverage: FDA drug approval, DEA scheduling, Oregon’s supervised psilocybin service-center framework, and Colorado’s Natural Medicine Health Act program. None of these is the same thing as the others, none creates the others, and movement in one category does not determine movement in another. As of mid-2026, psilocybin remained Schedule I federally, no psilocybin drug had been approved by the FDA, and state programs operated under state-only authority. [1] primary-regulatory FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order Link →
Four regulatory categories, four different questions
FDA drug approval is a federal determination that a specific drug product — such as COMP360 — is safe and effective for a specific indication, at a specific dose, under specific conditions of use. It authorizes a company to market and sell that product. It applies to the specific product reviewed, not to the underlying substance generally. [2] primary-legal Breakthrough Therapy designation Link →
DEA scheduling is a federal classification of controlled substances under the Controlled Substances Act. Psilocybin is Schedule I — meaning it is classified as having high abuse potential, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. FDA approval of a specific psilocybin drug product creates the factual basis for DEA to consider rescheduling the substance, but rescheduling requires a separate DEA action and does not automatically follow from approval.
Oregon’s supervised psilocybin services framework (Ballot Measure 109, 2020) created a state licensing system for supervised psilocybin sessions administered by licensed facilitators in licensed service centers. This is a state regulatory program that operates under Oregon law. It is not an FDA-approved treatment, it does not require FDA approval to operate, and the psilocybin used is not an FDA-approved drug product. [3] primary-regulatory Psychedelic Drugs: Considerations for Clinical Investigations Link →
Colorado’s Natural Medicine Health Act (Proposition 122, 2022) similarly created a state framework for supervised natural medicine services. The same distinctions apply.
| Category | Governing authority | What it authorizes | What it does not do |
|---|---|---|---|
| FDA drug approval | U.S. federal (FDA) | Marketing a specific drug product for a specific indication | General psilocybin legalization; state program authorization |
| DEA Schedule I | U.S. federal (DEA) | Classification of the substance | Block state programs from operating under state law |
| Oregon psilocybin services | Oregon state | Licensed supervised sessions in licensed service centers | Federal law compliance; FDA approval; insurance coverage |
| Colorado Natural Medicine | Colorado state | Licensed supervised services under CO law | Federal law compliance; FDA approval; insurance coverage |
What FDA approval would and would not change
If COMP360 receives FDA approval for treatment-resistant depression, it would become lawfully marketable as a prescription drug for that indication. Physicians could prescribe it. That approval would:
- Not automatically legalize psilocybin at the federal substance level (DEA action required)
- Not authorize Oregon or Colorado programs to use COMP360 without separate state/federal coordination
- Not apply to natural psilocybin mushrooms, dietary supplements, or other products
- Not constitute any approval for any other indication
The DEA has been directed by executive order to initiate a scheduling review once Phase 3 evidence is complete. That review has its own process and outcome, separate from the FDA approval action. [1] primary-regulatory FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order Link →
Why conflating these pathways matters
Conflating these categories leads to predictable misunderstandings. Reporting that “psilocybin was recognized by the FDA” for a BTD milestone implies an approval that has not happened. Describing an Oregon service-center session as “the same treatment studied in clinical trials” mischaracterizes both the product and the evidence. Assuming that a positive Phase 3 TRD result means state programs are now offering evidence-based medicine applies findings outside their scope.
These mischaracterizations matter because they affect how people reason about access, legality, safety, and evidence. None of the state programs offers an FDA-approved drug. None of the clinical trial results establishes what happens in uncontrolled, non-pharmaceutical-grade, state-regulated settings. Those are different questions requiring different evidence. See How to Read Press Releases for a framework on evaluating source language. See the Legal Status cluster for how legal status and safety evidence are distinct questions.
State programs and clinical trials are different contexts
State-licensed psilocybin sessions are not clinical trials. The legal context, the product, the protocol, the oversight structure, and the evidence base are all different. A person who participates in an Oregon or Colorado supervised session is not participating in an FDA-regulated clinical trial, and the outcomes of such sessions are not clinical trial data of the type that supports a regulatory application.
Clinical trial participants in programs like COMP005, COMP006, or uAspire are enrolled under IRB oversight, using FDA-authorized investigational drugs, under pre-specified protocols, with rigorous adverse event monitoring and pre-specified outcome measures. These are fundamentally different contexts with different legal structures, different protections, and different levels of evidentiary oversight.
See Legal Status overview for how federal and state law interact. See Is Psilocybin FDA Approved? for the current regulatory status. See the Access cluster for the broader availability and access framework.
- Schedule I controlled substance
- A federal DEA classification, not a medical determination. Rescheduling requires a DEA proceeding separate from FDA approval. State programs can operate under state law while the federal classification remains Schedule I.
- FDA marketing approval vs. state licensing
- FDA approval is a federal standard for a specific drug product. State licensing frameworks for supervised services are independent state regulatory systems that do not require and do not confer FDA approval.
- Preemption
- The general principle that federal law supersedes state law in areas where Congress has regulated comprehensively. The interaction between state psilocybin programs and federal scheduling is a live legal question; state programs operate in a space where federal enforcement has been limited, not where federal law has changed.
- Insurance coverage
- FDA-approved prescription drugs may be eligible for insurance coverage under applicable plans. State-licensed psilocybin services are not FDA-approved treatments and are generally not covered by insurance.